Danaher Co. (NYSE:DHR) Shares Sold by NorthRock Partners LLC

NorthRock Partners LLC reduced its stake in Danaher Co. (NYSE:DHR) by 33.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,623 shares of the conglomerate’s stock after selling 1,842 shares during the period. NorthRock Partners LLC’s holdings in Danaher were worth $1,007,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Fort Pitt Capital Group LLC boosted its stake in shares of Danaher by 3.2% in the third quarter. Fort Pitt Capital Group LLC now owns 238,092 shares of the conglomerate’s stock valued at $66,194,000 after purchasing an additional 7,421 shares during the period. Good Life Advisors LLC purchased a new stake in shares of Danaher during the third quarter worth about $217,000. Oak Thistle LLC purchased a new position in Danaher in the second quarter valued at about $363,000. Duality Advisers LP acquired a new stake in Danaher during the 1st quarter valued at approximately $5,573,000. Finally, Diversified Trust Co raised its position in shares of Danaher by 75.4% in the 2nd quarter. Diversified Trust Co now owns 4,360 shares of the conglomerate’s stock valued at $1,090,000 after purchasing an additional 1,874 shares in the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Stock Up 0.1 %

Shares of DHR traded up $0.30 during trading hours on Tuesday, hitting $247.48. 211,360 shares of the company were exchanged, compared to its average volume of 2,736,363. The company has a market cap of $178.75 billion, a PE ratio of 47.17, a PEG ratio of 4.55 and a beta of 0.85. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The firm’s 50 day moving average is $266.53 and its 200-day moving average is $260.74. Danaher Co. has a 52 week low of $192.35 and a 52 week high of $281.70.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same quarter in the previous year, the firm posted $2.02 earnings per share. Danaher’s revenue was up 3.1% compared to the same quarter last year. On average, equities research analysts forecast that Danaher Co. will post 7.51 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were issued a $0.27 dividend. The ex-dividend date of this dividend was Friday, September 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. Danaher’s dividend payout ratio (DPR) is currently 20.61%.

Insider Buying and Selling

In related news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 10.90% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on DHR. The Goldman Sachs Group lifted their price target on shares of Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. Bank of America raised their target price on Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. Wolfe Research upgraded Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective for the company in a report on Thursday, October 31st. UBS Group dropped their price target on Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a report on Wednesday, October 23rd. Finally, TD Cowen raised their price objective on Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research note on Wednesday, October 23rd. Six analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $287.16.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.